Florida Cancer Specialists

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Lung cancer2 trials
• Head and neck cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 23 trials
• Phase 33 trials
• Phase 11 trial

Status

• Active, not recruiting3 trials
• Completed3 trials
• Terminated1 trial

Lead sponsor

• Pfizer5 trials
• Bayer1 trial
• Seagen, a wholly owned subsidiary of Pfizer1 trial

Running trials

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

  NCT03052608· Phase 3· Pfizer· Source

Closed trials

• Terminated

  A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

  NCT04999202· Phase 1· Bayer· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

  NCT02007512· Phase 2· Pfizer· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Phase 2· Pfizer· Source